Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance(5) provided on December 17, 2024. The ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Reports Q4 revenue $17.8B, consensus $17.26B. Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “2024 was a strong year of ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Merck is pausing HPV vaccine shipments to China “until at least midyear” as it grapples with lower demand for the shot. The ...

Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in ...

Ono Pharmaceutical (OTCMKTS:OPHLF – Get Free Report) posted its quarterly earnings data on Monday. The company reported $0.21 EPS for the quarter, Zacks reports. Ono Pharmaceutical had a net margin of ...

Potential impacts of the tariffs include higher prices for drugs and medical supplies, and possible shortages.

The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.

BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.